Neurocrine Biosciences Stock In The News
| NBIX Stock | USD 126.59 1.32 1.03% |
Our overall analysis of Neurocrine Biosciences' news coverage and content from conventional and social sources shows investors' bearish mood towards Neurocrine Biosciences. The specific impact of Neurocrine Biosciences news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Neurocrine Biosciences' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Neurocrine Biosciences headlines in addition to utilizing other, more conventional financial analysis modules. Check out Neurocrine Biosciences Backtesting and Neurocrine Biosciences Hype Analysis. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.
Neurocrine |
Neurocrine Biosciences Today Top News and Investor Outlook
Neurocrine Biosciences Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Neurocrine and other traded companies coverage with news coverage. We help investors stay connected with Neurocrine headlines for the 28th of November to make an informed investment decision based on correlating the impacts of news items on Neurocrine Stock performance. Please note that trading solely based on the Neurocrine Biosciences hype is not for everyone as timely availability and quick action are needed to avoid losses.
Neurocrine Biosciences stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Neurocrine earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Neurocrine Biosciences that are available to investors today. That information is available publicly through Neurocrine media outlets and privately through word of mouth or via Neurocrine internal channels. However, regardless of the origin, that massive amount of Neurocrine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neurocrine Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neurocrine Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neurocrine Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neurocrine Biosciences alpha.
Neurocrine Largest EPS Surprises
Earnings surprises can significantly impact Neurocrine Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2010-10-28 | 2010-09-30 | 0.05 | 0.06 | 0.01 | 20 | ||
1997-10-31 | 1997-09-30 | 0.05 | 0.06 | 0.01 | 20 | ||
2014-04-30 | 2014-03-31 | -0.19 | -0.17 | 0.02 | 10 | ||
2012-07-31 | 2012-06-30 | -0.03 | -0.01 | 0.02 | 66 | ||
2011-07-28 | 2011-06-30 | 0.06 | 0.04 | -0.02 | 33 | ||
2013-10-29 | 2013-09-30 | -0.2 | -0.17 | 0.03 | 15 |
Neurocrine Biosciences Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Neurocrine Biosciences Stock. Current markets are slightly bearish. About 58% of major world exchanges and indexes are down. See today's market update for more information.
21st of November 2024
Helpr Employer-Subsidized Family Care App with Patented My Choice Technology Expands Servi... at businesswire.com
13th of November 2024
Spruce Biosciences SWOT analysis tildacerfonts fate hangs on Q4 trial results at investing.com
12th of November 2024
Voyager Reports Third Quarter 2024 Financial and Operating Results at finance.yahoo.com
8th of November 2024
Disposition of 5140 shares by Roberts Eiry of Neurocrine Biosciences at 77.81 subject to R... at finance.yahoo.com
4th of November 2024
Neurocrine Biosciences Presents New Data on INGREZZA Capsules at Psych Congress 2024 Major... at finance.yahoo.com
31st of October 2024
Neurocrine Biosciences Inc Q3 2024 Earnings Call Highlights Strong Sales and Strategic ... at gurufocus.com
18th of October 2024
Analysts revise AbbVie stock price target ahead of earnings at finance.yahoo.com
13th of September 2024
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses End... at benzinga.com
Neurocrine Biosciences Investors Sentiment
The influence of Neurocrine Biosciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Neurocrine. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Neurocrine Biosciences' public news can be used to forecast risks associated with an investment in Neurocrine. The trend in average sentiment can be used to explain how an investor holding Neurocrine can time the market purely based on public headlines and social activities around Neurocrine Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neurocrine Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neurocrine Biosciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Neurocrine Biosciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Neurocrine Biosciences.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neurocrine Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neurocrine Biosciences' short interest history, or implied volatility extrapolated from Neurocrine Biosciences options trading.
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.